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ABSTRACT 45 
 46 
Background 47 
From October 2013 to April 2014, French Polynesia experienced the largest Zika virus (ZIKV) outbreak 48 
ever described at that time. During the same period, an increase in Guillain-Barré syndrome (GBS) 49 
was reported, suggesting a possible association between ZIKV and GBS. 50 
 51 
Patients and Methods 52 
A case-control study was performed to identify the role of ZIKV and dengue virus (DENV) infection in 53 
developing GBS.  Cases were GBS patients diagnosed at the Centre Hospitalier de Polynésie Française 54 
during the outbreak period. Controls were age-, gender-, and residence-matched patients who 55 
presented at the hospital with a non-febrile illness (Control group 1 [CTR1]; n=98), and age-matched 56 
patients with acute ZIKV disease and no neurological symptoms (Control group 2 [CTR2]; n=70). 57 
Virological investigations included RT-PCR for ZIKV, and both microsphere immunofluorescent and 58 
seroneutralization assays for ZIKV and DENV. Anti-glycolipid reactivity was studied in GBS patients 59 
using both ELISA and combinatorial microarrays.   60 
 61 
Results 62 
Forty-two patients were diagnosed with GBS during the study period.  Ninety-eight percent of GBS 63 
patients had anti-ZIKV IgM or IgG, and all had neutralizing antibodies against ZIKV compared to 64 
55.7% with neutralizing antibodies in the CTR1 group (P<0.0001).  Ninety-three percent of GBS 65 
patients had ZIKV IgM and 88% had experienced a transient illness in median six days before the 66 
onset of neurological symptoms, suggesting recent ZIKV infection.  GBS patients had 67 
electrophysiological findings compatible with the acute motor axonal neuropathy (AMAN) type, and 68 
had rapid evolution of disease (median duration of the installation and plateau phases was 6 and 4 69 
days, respectively). Twelve (29%) patients required respiratory assistance. No patients died. Anti-70 
glycolipid antibody activity, notably against GA1, was found in 13 (31%) patients by ELISA and 19/41 71 
(46%) by glycoarray at admission. The typical AMAN-associated anti-ganglioside antibodies were 72 
rarely present. There was no significant difference in past dengue history between GBS patients and 73 
the two control groups.  74 
 75 
Conclusion 76 
This is the first study providing evidence for ZIKV infection causing GBS. As ZIKV is spreading rapidly 77 
across the Americas, at risk countries need to prepare for adequate intensive care beds capacity for 78 
managing GBS patients.  79 
 80 
 81 
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Background 83 
 84 
Zika virus (ZIKV) is an arthropod-borne virus (arbovirus) in the genus Flavivirus, family Flaviviridae.1  85 
ZIKV was first isolated from a Rhesus monkey in 1947 in the Zika forest of Uganda.2 The first human 86 
infection was reported in Nigeria in 1954.3 Like dengue (DENV) and chikungunya (CHIKV) viruses, ZIKV 87 
adapted from an ancestral transmission cycle involving non-human primates and a broad spectrum 88 
of canopy dwelling mosquito species as vectors to an urban / periurban cycle involving humans as 89 
reservoirs and widely distributed Aedes (Stegomyia) mosquitoes as vectors.4  90 
From the 1950s, ZIKV was only reported as circulating sporadically in Africa and South-East Asia.5 In 91 
2007, ZIKV was isolated for the first time in the Pacific, on the Micronesian island of Yap.6 From 92 
October 2013 to April 2014, French Polynesia experienced the largest Zika outbreak ever reported at 93 
that time.7 It was estimated that more than 32,000 patients consulted for suspected ZIKV infection, 94 
with a weekly incidence peaking on week 9 of the outbreak.8 From 2014, ZIKV spread to other Pacific 95 
islands, notably Easter island (Chile). In March 2015, Brazil reported autochthonous transmission of 96 
ZIKV,9 and an outbreak was declared 6 months later.10 As of February 1, 2016, ZIKV had emerged in 97 
25 countries and territories in South/Central America, with alarming reports of microcephaly cases 98 
among neonates in Brazil.11  99 
Previously to the French Polynesian outbreak, ZIKV infection used to be described as a mild febrile 100 
illness with clinical symptoms including maculopapular rash, joints and muscles pain, headache and 101 
non-purulent conjunctivitis.6 Between November 2013 and February 2014 in French Polynesia, 42 102 
patients presented at hospital with Guillain-Barré syndrome (GBS), an autoimmune disease causing 103 
acute or subacute flaccid paralysis, contrasting with reports of 5, 10, 3 and 3 in 2009, 2010, 2011, and 104 
2012, respectively.12 Other arboviral diseases like West Nile, Japanese Encephalitis, chikungunya and 105 
dengue had already been reported to sometimes cause GBS,13-16  but only during the outbreak in 106 
French Polynesia was this severe neurological complication first described associated with ZIKV 107 
infection.17 The temporal coincidence between the peaks in incidence of ZIKV and GBS cases, and 108 
also the concurrent circulation of DENV serotypes 1 and 318 suggested possible causal relationship 109 
between the three events. Using two control series, we addressed the hypothesis that ZIKV infection 110 
with or without DENV concurrent or sequential infection may be a risk factor for the development of 111 
GBS. 112 
113 
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Methods 114 
 115 
Study design and participants 116 
A case-control study was performed to identify the role of ZIKV and dengue virus (DENV) infection in 117 
developing GBS.  Cases were GBS patients diagnosed at the Centre Hospitalier de Polynésie Française 118 
in Papeete, Tahiti, during the outbreak period. As a routine, all patients with suspicion of GBS in 119 
French Polynesia are referred to the CHPF for diagnosis confirmation.  All of the patients included in 120 
this study were diagnosed as developing a GBS by neurologists or staff in intensive care units 121 
according to international criteria.19 Clinical and demographic data were collected from medical 122 
records obtained during patients’ hospitalisation. The data recorded for all patients included: 123 
patient’s age, gender, island of residence, medical history and co-morbidities, clinical signs and 124 
symptoms, illness duration and severity. Electrophysiological assessment was performed for all 125 
patients using standard electromyography [EMG] techniques including motor nerve conduction 126 
studies of the median nerve (recording of the abductor pollicis brevis), the ulnar nerve (recording of 127 
the abductor digiti minimi) and the peroneal nerve (recording of the extensor digitorum brevis), as 128 
well as sensory nerve conduction studies in radial and sural nerves. 129 
To estimate the proportion of ZIKV infections in the general population, to be further compared with 130 
the GBS series, a first control group (CTR1, n=98) was recruited among patients hospitalised or 131 
consulting for non-febrile illness at the CHPF.  Patients from the CTR1 group were matched for age 132 
(±10 years), gender and island of residence with patients in the GBS group. Each patient in CTR1 133 
group had a blood sample taken ±7 days from the admission date of the matching GBS case. 134 
To investigate a possible role of past DENV infection(s) in developing a GBS in ZIKV infected patients, 135 
a second control group (CTR2, n=70) was recruited among age-matched (± 10 years) patients with 136 
RT-PCR-confirmed ZIKV infection, but who did not develop any neurological complication. 137 
The epidemic curve of ZIKV in French Polynesia was obtained by extrapolating data from a sentinel 138 
network of clinicians who have been reporting the number of suspected ZIKV cases on a weekly basis 139 
from October 2013 until April 2014 to the Bureau de Veille Sanitaire – Direction de la Santé de 140 
Polynésie Française.  141 
 142 
Zika and dengue virus infection diagnosis 143 
For the GBS group, a first blood sample was collected at hospital admission and one to three 144 
additional blood samples were collected three weeks, two and/or three months later. For the CTR1 145 
group, the blood sample was collected within a 7-day period from the indexed GBS case for 59 146 
(60.2%) patients, and with a median (IQR) period of 13 (9-16) days for the remaining controls.   147 
Diagnosis of ZIKV acute infection in patients from GBS and CTR2 groups was performed using a ZIKV 148 
specific RT-PCR protocol adapted from Lanciotti et al.20 Serum was considered positive for ZIKV if the 149 
two distinct genomic regions targeted by the RT-PCR were amplified.  150 
Detection of IgM against ZIKV and DENV in blood samples from patients in GBS and CTR1 groups was 151 
performed using indirect immunofluorescent assay (IFA) on Vero cells (African Green Monkey kidney 152 
cells) infected with either ZIKV[PF13-251013-18] or DENV[D1-Hawaii 1944]. 153 
Detection of IgG against ZIKV and each of the four DENV serotypes was performed on blood samples 154 
from patients in GBS, CTR1 and CTR2 groups using a recombinant-antigen based microsphere 155 
immunoassay (MIA) adapted from Beck et al.21 (see details in Supplementary material). 156 
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Detection of neutralizing antibodies against ZIKV and each of the four DENV serotypes was 157 
performed for patients in the GBS and CTR1 groups using a microseroneutralization assay performed 158 
on Vero cells inoculated with serial dilutions of each serum previously incubated with titrated 159 
ZIKV[PF13-251013-18] or DENV serotype 1 to 4 strains that were isolated during previous outbreaks 160 
in French Polynesia (see details in Supplementary material). 161 
 162 
Immunochemical reaction with glycolipids 163 
The sera from both GBS patients (n=42 at admission, n=31 at 3 months) and healthy blood donors 164 
(collected prior to April 2013; n=20) were tested by ELISA (Bühlmann-Gangliocombi®) for IgG/IgM 165 
reactivity to the glycolipids GM1, GA1, GM2, GD1a, GD1b and GQ1b at 1:100 dilution. As per kit 166 
instructions, results were considered as positive, equivocal, and negative when showing >50%, 30-167 
50%, and <30% binding, respectively.  Sera (n=41 at admission, n=27 at three months) were also 168 
tested by a combinatorial microarray screening method based on a refinement and miniaturization 169 
of previous published combinatorial glycoarray assay22 (see details in Supplementary material). 170 
 171 
Immunosuppression test for exploration of molecular mimicry mechanisms 172 
The sera from six patients showing high reactivity towards GA1 were tested against ZIKV viral 173 
proteins by Western blot (see details in Supplementary material). Molecular mimicry was evaluated 174 
using the method by Neil.23 (see details in Supplementary material).  175 
  176 
Sample size 177 
The primary objectives of this study were to determine the association between GBS and ZIKV 178 
infection in French Polynesia and to determine whether possible co-infection or pre-existing 179 
immunity to dengue (and a specific DENV serotype) appear to facilitate the development of GBS. 180 
With two controls per case, and on the assumption that 70% of GBS patients and 40% of controls 181 
reported a recent ZIKV infection, the statistical power to detect a difference between the GBS group 182 
and the control group was calculated to be 86%.  183 
 184 
Statistical analysis 185 
The risk of developing GBS per ZIKV infection was calculated by dividing the total estimated number 186 
of GBS cases reported in French Polynesia (n=42) by the total number of people infected by ZIKV 187 
during the epidemic period.  This latter number was calculated by multiplying the attack rate (66%) 188 
estimated during a post epidemic population-based serological survey24 by the total population of 189 
French Polynesia (268 270 inhabitants; 2012 census). The association between ZIKV positive serology, 190 
DENV positive serology, and GBS was analysed using exact conditional logistic regression. As the 191 
humoral response elicited by acute ZIKV infection may trigger production of anti-DENV IgG related to 192 
past DENV infections, we adjusted the odds-ratio (OR) describing the association between anti-DENV 193 
IgG and GBS for the presence of anti-ZIKV IgG.  All ORs are given with their 95% confidence intervals. 194 
Motor nerve conduction parameters values were compared to reference values using one-sample t 195 
tests, and 1st week values were compared to 4th month values using Wilcoxon matched pairs signed 196 
rank sum tests. First week values of the 19 patients with electrophysiological measurements at 4th 197 
month were compared to those of the 18 patients without follow-up using a Mann Whitney test.     198 
Data were collected using EpiData 3.1 software and all statistical analyses were performed using 199 
STATA 14, StataCorp LP. 200 
 201 
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Ethical considerations 202 
The study protocol was approved by the Comité d’Ethique de la Polynésie française (N°69/CEPF 203 
2014), and all patients provided informed consent for their participation in the study. 204 
 205 
Role of the funding source 206 
The funders had no role in the design of the study, data collection, data analysis, data interpretation, 207 
or writing of the report.  The corresponding author had full access to all the data in the study, except 208 
for the results of the combinatorial microarray (HSK & HW), and had final responsibility for the 209 
decision to submit the publication. 210 
211 
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Results 212 
 213 
Epidemiological dynamics of the outbreak 214 
Cases of ZIKV infection were reported weekly from October 2013 until March 2014 (See Figure 1). 215 
The first GBS case was reported on week 5 of the outbreak, while the peaks of the Zika epidemic and 216 
GBS cases were reached on week 9 and 12, respectively.  In total, 42 cases of GBS were recorded 217 
during the ZIKV outbreak. Based on a 66% attack rate of ZIKV infection in the general population, the 218 
risk of GBS was estimated at 0.24 per 1000 ZIKV infections.   219 
 220 
Patients characteristics 221 
The median (IQR) age of GBS patients was 42 (36-56) years, 31 (74%) were males and 38 (90%) were 222 
born in French Polynesia .  223 
The clinical characteristics of the patients in the GBS group are shown in Table 1.  Most (88%) had a 224 
recent history of viral syndrome, in median 6 days prior to the onset of neurological manifestations.  225 
Rash (81%), arthralgia (74%), fever (58%) were the most commonly reported symptoms. 226 
The main characteristics of the GBS were the rapid progression to nadir (median of 6 days between 227 
the onset of neurological symptoms to the nadir), and the short plateau phase (median of 4 days). 228 
Clinical presentation at admission was manifested by generalised weakness (74%), with incapacity to 229 
walk (44%). Facial palsy was common (64%). Ninety three percent of the patients had increased (> 230 
0.52 mg/dL) protein concentration in the cerebrospinal fluid obtained by lumbar puncture.  Sixteen 231 
(38%) patients were admitted to intensive care unit, and 12 (29%) required respiratory assistance.  232 
All GBS cases received treatment by immunoglobulins, and one had plasmapheresis. The median 233 
duration of hospitalisation was 11 days for all patients, and 51 days for the 16 patients who were 234 
admitted into intensive care.  No patients died.  Three months after discharge, 24 (43%) patients 235 
were able to walk without assistance. 236 
 237 
ZIKV and DENV infection diagnosis 238 
Acute ZIKV infection, as confirmed by a positive RT-PCR result, was observed for all patients in the 239 
CTR2 group, but for none of the 41 patients tested in the GBS group (Table 2A); thus corroborating 240 
clinical observations, notably the absence of fever, suggesting that the patients in the GBS group 241 
were no longer viremic at admission.  242 
Recent infection by ZIKV was supported by the detection of anti-ZIKV IgM antibodies in 92.9% and 243 
17.3% of the patients in GBS and CTR1 groups, respectively (Table 2A). As possible cross-reactivity 244 
between anti-DENV and anti-ZIKV IgM responses had previously been described, IFA was performed 245 
using the two viruses. In the GBS group, 73.8% of the patients had IgM against ZIKV but not against 246 
DENV. All 19.1% patients with anti-DENV IgM also had IgM against ZIKV, suggesting that the anti-247 
DENV IgM response could result from cross-reactivity.  248 
 249 
When combining the results of both anti-ZIKV IgM and IgG, previous occurrence of a ZIKV infection 250 
was suggested for 97.6% of the patients in the GBS group and 35.7% in the CTR1 group (OR [95% CI] 251 
= 59.7 [10.4 - +∞]; P<0.0001; Table 2C). Moreover, a neutralizing response against ZIKV was observed 252 
for 100% of the patients in the GBS group and 55.7% in the CTR1 group (OR [95% CI] = 34.1 [5.8 - 253 
+∞]; P<0.0001).  254 
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The interpretation of anti-DENV IgM is difficult due to possible cross-reactivity with anti-ZIKV IgM.  255 
Still, there was no indication of increased recent infection with DENV among GBS patients when 256 
compared to the CTR1 group (Table 2A; P>0.05).  Past history of dengue was common among GBS 257 
patients (95.2% on the last sample available, away from the immunological boost associated with 258 
recent ZIKV infection).  It was non significantly different from that of the CTR1 group (88.8%; OR [95% 259 
CI] = 2.0 [0.4 – 19.9]; P = 0.62) and the CTR2 group (82.9%; OR [95% CI] = 6.04 [0.81 – 269.5]; P = 260 
0.10) (Table 2C and Suppl. Table 1).  These non significant differences were further attenuated after 261 
stratifying by the presence of anti-ZIKV IgG, suggesting that the humoral response elicited by ZIKV 262 
infection also triggered production of anti-DENV IgG (Table 2B & 2C).  This is corroborated by the 263 
examination of ZIKV and DENV IgG responses in the blood samples serially collected from the GBS 264 
patients.  Indeed, the number of patients with anti-ZIKV IgG increased from the earliest to the 265 
intermediate and then to the latest sample, while the reverse occurred for anti-DENV IgG (Suppl. 266 
Table 1 & Suppl. Table 2). A possible explanation would be that an anamnestic anti-DENV IgG 267 
response in GBS patients might have been transiently boosted by the ZIKV infection. 268 
Serological tests for Campylobacter jejuni (n=41), HIV (n=42), cytomegalovirus (n=32), Epstein-Barr 269 
virus (n=32) and herpes simplex virus type 1 and 2 (n=8) were negative.  270 
 271 
Neurophysiological assessment 272 
A total of 37 patients underwent electrophysiological examination during the first week after GBS 273 
onset (Table 3). Motor nerve conduction study showed the same pattern in all tested nerves, with 274 
prolonged distal latencies (p<0.0001) and marked reduction of the distal compound muscle action 275 
potential (CMAP) amplitude (p<0.0001), indicative of severe conduction alteration in the distal nerve 276 
segments. By contrast, there was no significant conduction slowing or block in intermediate motor 277 
nerve segments (throughout forearm and legs). Amplitude and conduction velocity of sensitive 278 
potentials were not significantly altered in radial and sural nerves.   279 
A second nerve conduction study was performed four months later including 19 GBS patients for 280 
whom a baseline assessment was available (there was no difference in baseline values of the 19 281 
patients with follow-up compared the 18 without follow-up). By comparison to the first study, results 282 
showed a clear improvement of the distal conduction abnormalities (P<0.001), with reduction of the 283 
prolonged distal latencies and near normalization of CMAP amplitudes (Table 3 and Suppl. Figure 1).  284 
Altogether, these findings are suggestive of an acute motor axonal neuropathy (AMAN).  285 
 286 
Detection of reactivity towards glycolipids by ELISA 287 
By ELISA, at admission, sera from 13 (31%) GBS patients showed a positive reactivity (% of binding 288 
>50%) against different glycolipids (Table 4 and Suppl. Table 2). Ten (24%) had an equivocal 289 
percentage of binding (between 30 and 50%). Among these 23 patients, 17 had a reactivity directed 290 
toward glycolipid GA1 (8 positive, 9 equivocal) and it was either isolated or shared with other 291 
glycolipids. At three months, the proportion of reactive sera had slightly increased (48%). Controls 292 
were negative (n=20). These results were heterogeneous and low intensity for 50% of them. 293 
 294 
Test of reactivity of GBS patient’s sera with ZIKV viral proteins by Western blot 295 
Western blot was used to test the reactivity against ZIKV viral proteins in the serum from 6 GBS 296 
patients, 4 with high reactivity against GA1 (patients 6, 11, 20 and 29 of Suppl. Table 2), and 2 297 
patients with no reactivity against GA1 (patients 13 and 27 of Suppl. Table 2).  All sera showed 298 
intense reactivity with viral proteins regardless of their reactivity towards GA1 (Suppl.  Figure 2).   299 
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 300 
Determination of specific interaction to GA1 by serum absorption with GA1 301 
The reactivity of serum n°20 towards ZIKV proteins was not inhibited even at the highest GA1 302 
amount (600 µg; Suppl. Figure 3). We further tested serum n°6 and did not observe any competition 303 
with a GA1 amount of 300 µg (data not shown). 304 
 305 
Detection of reactivity towards glycolipids by combinatorial microarray 306 
Combinatorial microarrays were used for screening glycolipid complexes as antigens. The majority of 307 
serum samples tested was negative or had low level binding to some single and or heteromeric 308 
glycolipid complex. Notably, antibodies against GA1:sulphatide complex were frequently observed 309 
(19/41; 46.3%) in patient sera, with intermediate binding intensities, above the threshold of 310 
positivity (p=0.001). In addition, a significant number of patient sera had antibodies raised against 311 
GA1 in complex with cholesterol and/or phosphatidylserine, although most were of low binding 312 
intensity (see Supplementary material and Suppl. Figure 4).  313 
 314 
315 
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Discussion 316 
 317 
This is the first study to evaluate the role of ZIKV infection in a large number of GBS patients 318 
diagnosed during a ZIKV outbreak.  The serological investigations conducted on the blood samples 319 
from the 42 patients who developed a GBS during the French Polynesian ZIKV outbreak confirm that 320 
all these patients have experienced ZIKV infection. Moreover, the presence of IgM  (92.9%) and the 321 
information that most (88%) patients reported a transient viral syndrome compatible with ZIKV 322 
disease in median 6 days prior to the onset of neurological symptoms, suggested a recent ZIKV 323 
infection.  GBS patients were no longer viremic for ZIKV at the time of admission, consistent with 324 
previous data showing that ZIKV viremia rarely exceeds five days after disease onset.25 However, 325 
detection of virus in urine by RT-PCR may be a valuable alternative.26  As DENV 1 and 3 serotypes 326 
were co-circulating at the time of the ZIKV epidemic,18 we investigated whether DENV infection 327 
might have contributed to the occurrence of GBS. Analysis of dengue serology (IFA, MIA, 328 
seroneutralization) did not support recent DENV infection. Most (95.2%) of the GBS patients had pre-329 
existing dengue immunity, but this did not appear as being significantly different from the control 330 
groups. 331 
 332 
GBS is an acute, immune-mediated polyradiculoneuropathy typically arising after minor viral and 333 
bacterial infections. Motor function is usually affected, beginning distally and progressing proximally 334 
over up to a 4-week period.27 Patients suffer from generalised weakness, areflexia and varying 335 
degree of sensory disturbances and involvement of cranial nerves.28 The risk of GBS increases with 336 
age and men are more commonly affected than women.29 The pathophysiology is incompletely 337 
understood, but is known to mostly occur 2-8 weeks after an infection. GBS is the leading cause of 338 
non-traumatic paralysis, with a global incidence of 1-4 per 100,000 persons-years. The range of 339 
infections reported to have preceded GBS include upper respiratory infections, notably influenza and 340 
pseudo-influenza, digestive tract infections, notably Campylobacter jejuni, as well as cytomegalovirus 341 
and Epstein-Barr virus infections.30-32 The incidence rate of GBS cases during the French Polynesian 342 
outbreak was estimated at 0.24 per 1,000 ZIKV infections, at the lower range of the 0.25 to 0.65 per 343 
1,000 observed following C. jejuni infections.33 It is unlikely that GBS cases were missed during the 344 
study period, since routine procedures for systematic confirmation of GBS diagnosis pre-existed the 345 
ZIKV epidemic, and all cases were systematically referred to the CPHF for diagnosis confirmation.  346 
While it is unknown whether attack rates of ZIKV epidemics will be as high in Latin America affected 347 
regions as compared to Pacific islands (73% in Micronesia6 and 66% in French Polynesia24), high 348 
number of GBS cases may be expected in the coming months as the result of this association.  The 349 
results of our study support that ZIKV should be added to the list of infectious pathogens susceptible 350 
to cause GBS. 351 
 352 
GBS patients in the present series had electrophysiological findings compatible with the AMAN type. 353 
EMG assessments performed during the first week of the disease showed marked distal motor nerve 354 
conduction alterations, which explain the neuromuscular weakness. Prolonged distal latencies and 355 
reduced distal CMAP amplitude may have been as first interpreted as demyelinating conduction 356 
slowing and block, leading to classify the GBS pattern as acute inflammatory demyelinating 357 
neuropathy (AIDP) with possible axonal degeneration. However, the disappearance of the distal 358 
motor conduction alterations during the follow-up in a subset of patients, without development of 359 
abnormal temporal dispersion or conduction slowing in intermediate nerve segments, was consistent 360 
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with “reversible conduction failure” already described in AMAN.34,35 In GBS patients, such 361 
nodal/paranodal dysfunctions would be rather strictly localized in distal motor nerve endings.36 The 362 
clinical outcome of these ZIKV GBS patients was generally favourable, despite a rapid onset and short 363 
plateau phase, as may be seen in other patient groups suffering from the AMAN type of GBS.37 Three 364 
months after discharge, 43% of the patients were able to walk without assistance.   365 
 366 
Among the molecular mechanisms contributing to the pathogenesis of GBS, a broad range of anti-367 
glycolipid IgG antibodies, notably directed to gangliosides, has been previously described, particularly 368 
in axonal variants of the disease.38,39 Results in this current study, using both ELISA and combinatorial 369 
microarray techniques found less than 50% of sera at admission with a significant autoimmune 370 
response against glycolipids, including gangliosides and/or glycolipid complexes (see supplementary 371 
material). This low detection rate for the AMAN clinical subtype, may be a reflection of the unique 372 
nature of the preceding infection and study population, in contrast with more typical post-373 
Campylobacter GBS/AMAN clinical cohorts. These findings suggest that there may be autoantibodies 374 
in this post-ZIKV GBS cohort that cannot be fully identified by current methods. Moreover, 375 
complementary analysis of sera with reactivity against GA1 did not reveal any competition between 376 
GA1 and ZIKV proteins, thus suggesting the lack of antigenic mimicry between ZIKV antigens and GA1 377 
in these GBS patients and casting doubt on the relevance of the anti-GA1 antibodies to neuropathy 378 
pathogenesis. The disease may not be anti-glycolipid antibody mediated, rather be mediated by 379 
other autoantibody specificities or unknown neurotoxic factors. Alternatively viral neurotoxicity may 380 
contribute a more direct but as yet unexplained role. 381 
 382 
Because almost all of the GBS patients were of Polynesian origin and as distribution of HLA alleles 383 
had been previously described as being involved in certain forms of GBS,40 a possible role of ethnicity 384 
in triggering GBS was hypothesized. However, the high incidence of GBS recently reported in Brazil, El 385 
Salvador and Columbia during local ZIKV outbreaks11,41 suggests that, whenever involved, such host 386 
factors may not be specific to the ethnic groups living in French Polynesia.  387 
In conclusion, this is the first study to document a large series of patients who developed a GBS 388 
following ZIKV infection, a virus that previously used to be considered as causing only mild disease. 389 
Most (88%) of the GBS patients reported symptomatic ZIKV infection that preceded by a median of 6 390 
days the occurrence of neurological symptoms. All GBS were of the AMAN type, characterised by 391 
distal motor nerve involvement, the absence of typical patterns and levels of anti-glycolipid 392 
antibodies, and faster recovery than usually observed in typical GBS.  As ZIKV is spreading rapidly 393 
across the Americas, at risk countries need to prepare for adequate intensive care beds capacity for 394 
managing GBS patients.  395 
 396 
 397 
 398 
 399 
 400 
  401 
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FIGURE LEGENDS 519 
 520 
Figure 1: Epidemic curve of ZIKV virus suspected cases and Guillain-Barré syndromes in French 521 
Polynesia 2013-2014.  ZIKV cases are shown in orange and GBS cases in black 522 
 523 
Suppl. Figure 1 524 
Changes in motor conduction study in one of the patients. Stimulation of right ulnar nerve at wrist 525 
and elbow, recording of the abductor digiti minimi. A : 5 days after paralysis onset : CMAP amplitude 526 
: 1.5 mV, distal motor latency (DML) : 4.1 ms, motor conduction velocity (MCV) : 50 m/s. Calibration 527 
2 mV/div., 5 ms/div. B : 3 months later : CMAP amplitude : 8.1 mV, DML : 3.4 ms, MCV : 49 m/s. 528 
Calibration 5 mV/div., 5 ms/div. 529 
 530 
Suppl. Figure 2. Test of reactivity of ZIKV positive patients’ sera towards ZIKV viral proteins by 531 
Western Blot 532 
Lanes 1 and 2: non heated and heated control cell extracts; lanes 3 and 4: non heated and heated 533 
ZIKV positive cell extracts. 534 
A: Coomassie stained SDS PAGE 535 
B: Western Blot revealed by using anti-ZIKV 4G2 monoclonal antibody 536 
Sera 6, 11,20, 29: GA1+ patients 537 
Sera 13, 27: GA1- patients 538 
 539 
Suppl. Figure 3: Competition experiments using GA1 540 
Patient’s serum was incubated in presence of various amounts of GA1: 100 µg (B); 300 µg (C), 600 µg 541 
(D). A: control without GA1. 542 
 543 
Suppl. Figure 4: Combinatorial microarray heatmaps 544 
 17 
Each patient and healthy control serum was screened against 78 single and heteromeric glycolipid 545 
targets on a microarray assay. For ease of comparison, IgG (A) and IgM (B) data was visually 546 
displayed as heat maps, in which the rainbow scale was used to assign a colour to each interaction, 547 
which indicated the intensity of the antibody binding for that target. 548 
549 
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Table 1: Clinical characteristics of patients with GBS (n=42) in French Polynesia 2013-2014 550 
  n (%) or median IQR 
Age (years) 42 36-56 
Male sex 31 (74)  
Obesity 11 (26)  
Smoking (n=40) 12 (30)  
High Blood Pressure 7 (17)  
Heart disease 3 (7)  
   
Previous viral syndrome 37 (88)  
Conjunctivitis (n=31) 15 (48)  
Rash (n=36) 29 (81)  
Fever (n=31) 18 (58)  
Arthalgia (n=31) 23 (74)  
Edema of the limbs (n=29) 9 (31)  
   
Time between reported viral syndrome and onset of 
neurological symptoms (days) (n=37) 
6 4-10 
Time between onset of neurological symptoms and 
admission (days) 
4.5 2-8 
   
   
Symptoms at admission   
Muscle weakness 31 (74)  
Symmetric muscle weakness  27 (64)  
Muscle weakness limited to lower limbs 18 (43)  
Incapacity to walk (n=41) 18 (43)  
Areflexia or decreased reflexes 26 (62)  
Facial palsy 27 (64)  
Bilateral facial palsy 14 (33)  
Unilateral facial palsy 13 (31)  
Trouble swallowing 10 (24)  
Paresthesia 35 (83)  
   
Time between onset of neurological symptoms and 
peak of illness (days) 
6 4-9 
Time between admission and peak of illness (days) 1 0-2 
   
Symptoms at nadir   
Muscle weakness 36 (86)  
Symmetric muscle weakness  33 (79)  
Muscle weakness limited to lower limbs 17 (40)  
Incapacity to walk 26 (62)  
Areflexia or decreased reflexes 20 (48)  
Facial palsy 33 (79)  
Bilateral facial palsy 25 (60)  
Unilateral facial palsy 8 (19)  
Trouble swallowing 19 (45)  
 19 
Trouble breathing 14 (33)  
Duration of plateau phase of illness (days) 4 3-10 
   
Treatment   
Intravenous immune globulins 42 (100)  
Plasmapheresis 1 (2)  
   
Patients admitted to intensive care 16 (38)  
Trouble swallowing 12 (29)  
Respiratory assistance 12 (29)  
   
Duration of hospitalisation (days) 11 7-20  
Duration of hospitalisation for patients  admitted to 
intensive care (days) 
51 16- 70 
   
Lumbar puncture results   
Proteins (mg/dL) 1.47 0.92-2.21 
Increased CSF protein concentration  
(cut-off : 0.52 mg/dL) 
39 (93)  
Cells (/mm3) 4 1-7 
 
 551 
 552 
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 Table 2. Results of molecular and immunological analyses of GBS and control patients in French Polynesia 2013-2014  
 
 Zika  
IgM Zika/ IgM Dengue n (%) 
 vRNA  IgM  IgG  IgM/IgG  Neut.  
  n (%)   n (%)   n (%)   +/+ +/- -/+ -/- ZIKV
+ n (%)   n (%)   +/+ +/- -/+ -/- 
GBS (N=42a) 0 (0)  39 (92.9)  29 (69.0)  27 12 2 1 41 (97.6)  42 (100)  8 (19.1) 31 (73.8) 0 (0) 3 (7.1) 
CTR1 (N=98) ND  17 (17.3)  25 (25.5)  7 10 18 63 35 (35.7)  54 (55.7)  6 (6.1) 11 (11.2) 8 (8.2) 73 (74.5) 
CTR2 (N=70) 70 (100)   ND   5 (7.1)   ND ND ND ND ND   ND   ND ND ND ND 
Table 2A. Detection of Zika RNA (RT-PCR), Zika & Dengue IgM (IFA), Zika IgG (MIA) and neutralizing antibodies (Neut). 
a
RT-PCR was only performed for 41 GBS patients; tested samples for GBS patients are late samples (±3 months after admission), except for the RT-PCR (admission sample)  
  IgG Dengue n (%)  Dengue Neut.                 
n (%) 
 
GBSa  CTR1  CTR2  
  IgG Z-b IgG Z+b Total  IgG Z- IgG Z+ Total  IgG Z- IgG Z+ Total  GBS 
≥ 2 serotypes 11 (84.6) 25 (86.2) 36 (85.7)  42 (57.5) 23 (92.0) 65 (66.3)  42 (64.6) 4 (80.0) 46 (65.8)  41 (100) 
1 serotype 0 - 4 (13.8) 4 (9.5)  20 (27.4) 2 (8.0) 22 (22.5)  11 (16.9) 1 (20.0) 12 (17.1)  0 - 
No infection 2 (15.4) 0 - 2 (4.8)  11 (15.1) 0 - 11 (11.2)  12 (18.5) 0 - 12 (17.1)  0 - 
  13  29  42   73  25  98   65  5  70   41  
Table 2B. Dengue IgG (MIA) and neutralizing responses (Neut) 
a
tested samples for GBS patients are late samples (±3 months after admission); 
b
IgG Z- and IgG Z+ mean samples IgG (MIA) negative and positive for ZIKV, respectively.   
 
 GBSa 
(n=42) 
 
CTR1 
(n=98) 
OR [95% CI] ORa [95% CI] 
CTR2 
(n=70) 
OR [95% CI] ORa [95% CI] 
 n (%)  n (%)   n (%)   
ZIKV IgM and/or IgG positivity 41 (97.6)  35 (35.7) 59.7 [10.4 - +∞]     
Positive ZIKV seroneutralization 42 (100.0)  54 (55.7) 34.1 [5.8 - +∞]     
DENV IgG positivity 40 (95.2)  87 (88.8) 2.0 [0.4 - 19.9] 1.0 [0.2 - 11.5] 58 (82.9) 6.0 [0.8 - 269.5] 4.0 [0.5-184.7] 
Table 2C: ZIKV and DENV serological patterns associated with GBS 
a
Tested samples for GBS patients are late samples (±3 months after admission); 
b
Adjusted for ZIKV IgG positivity 
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Table 3: Evolution of motor nerve conduction parameters (mean values) after GBS onset. 
 
  Median  Ulnar  Fibular 
   
DML  
(ms) 
 
Ampli 
(mV) 
 
MCV 
(m/s) 
  
DML  
(ms) 
 
Ampli 
(mV) 
 
MCV 
(m/s) 
  
DML  
(ms) 
 
Ampli 
(mV) 
 
MCV 
(m/s) 
   
N < 3.7 
 
N > 6.0 
 
N > 48 
  
N < 3.0 
 
N > 6.0 
 
N > 48 
  
N < 5.0 
 
N > 3.0 
 
N > 42 
1st week 
n = 37 
 
12.4a 2.9a 47  5.8a 3.9a 52  9.9a 2.4c 41 
1st week 
subgroup
n = 19 
 
14.1a 2.4a 45  6.1a 3.7b 49  10.1c 2.1c 39 
4th month 
n = 19 
 
7.1c 6.0c 47  4.4c 5.6c 46  6.0c 3.8c 46 
DML: distal motor latency. Ampli : amplitude of the distal compound muscle action potential. MCV: motor conduction 
velocity.  
1
st
 week values are compared to reference values; 4
th
 month values are compared to 1
st
 week values of the same subgroup 
(n=19) 
a 
P < 0.0001; P < 0.001; 
c 
P < 0.05. 
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Table 4: Positive (>50%) reactivity to glycolipids in sera of GBS patients (n=42) and controls (n=20) in 
French Polynesia 2013-2014 
  
    GBS at onset           GBS at 3 months             Controlsa  
          (n=42)                         (n=31)                        (n=20) 
             n (%)                            n (%)                           n (%) 
Glycolipid  
  GM1             0 (0)                           8 (26)                           0 (0) 
  GA1             8 (19)                       10 (32)                          0 (0) 
  GM2             2 (5)                           1   (3)                           0 (0)  
  GD1a             5 (12)                         9 (29)                           0 (0) 
  GD1b             3 (7)                           9 (29)                           0 (0) 
  GQ1b             0 (0)                           0   (0)                           0 (0) 
    Any           13 (31)                       15 (48)                          0 (0) 
a
Blood donors 
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Figure 1: Weekly cases of suspected Zika virus infections and Guillain-Barré syndromes in French 
Polynesia from October 2013 until April 2014 
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Supplementary material 
 
ZIKV and DENV infection diagnosis 
Detection of IgM against ZIKV and DENV was performed using indirect immunofluorescent assay 
(IFA) on the blood samples from patients in both GBS and CTR1 groups. Briefly, ZIKV [PF13-251013-
18] isolated during the epidemic in French Polynesia1 and DENV [D1-Hawaii 1944 reference strain] 
were independently inoculated onto Vero cells (African Green Monkey kidney cells). One week later, 
ZIKV- or DENV-infected cells were fixed on microscope slides and exposed to sera, and the presence 
of anti-ZIKV or anti-DENV IgM was revealed by incubation with goat anti-Human IgM antibody, FITC 
conjugate (Novex, Life technologies). 
Detection of IgG against ZIKV and each the four DENV serotypes was performed on blood samples 
from patients in GBS, CTR1 and CTR2 groups using a recombinant-antigen based SHERPAxMap 
microsphere immune assay (MIA) adapted from Beck et al.2 and detailed in Vanhomwegen J.3 Briefly, 
sera were diluted 1/400 and incubated with a mix of microspheres coupled with either DENV-1, -2, -
3,- -4 or ZIKV   recombinant antigens (E protein domain III) produced in Drosophila S2 expression 
system. Detection of anti-DENV-1,-2,-3,-4 or anti-ZIKV IgG was performed using a Biotin-SP-
conjugated Goat Anti-Human IgG antibody (Jackson ImmunoResearch) and streptavidin, R-
phycoerythrin conjugate (SAPE, Life Technologies). The median fluorescence intensity was read on a 
MagPix instrument (Bio-Rad Laboratories). The cut-off of the MIA was determined by ROC curve 
analysis for all the antigens using positive and negative control sera. 
 
Detection of neutralizing antibodies against ZIKV and each of the four DENV serotypes was 
performed for patients in GBS (latest blood sample) and CTR1 groups. Briefly, Vero cells cultured on 
96-well plates were inoculated with serial dilutions of each serum previously incubated with titrated 
ZIKV [PF13-251013-18], DENV-1 [PF15-080108-88], DENV-2 [PF96-300896-243/158], DENV-3 [PF90-
300190-30/56] or DENV-4 [PF09-290509-104]. One week later, infected cells were detected by ELISA 
using primary mouse pan-flavivirus E mAb 4G2 which reacts with ZIKV E protein4 and a secondary 
goat anti-mouse IgG HRP-conjugated antibody (Santa Cruz). The neutralizing antibody titer was 
defined as the inverse of the latest serum dilution that inhibited the virus. 
 
Reactivity of sera with ZIKV by Western blot 
ZIKV [PF13-251013-18]1 was used to infect BHK21 and Vero cells with a MOI of 1 for 1hr at 37°C. 
Fresh medium was added and after 48h of incubation, the supernatant was removed, the cells were 
washed three times with PBS and collected in RIPA buffer. The cell extract was centrifuged 10 min at 
4000g and the supernatant was kept at -80°C. 
 
ZIKV cell extracts were mixed with LDS buffer and was or not heated 10 min at 95°C. Non-infected 
BHK21 and Vero cells extracts were used as control. Viral proteins recognised by patients’ antibodies 
were detected by Western blot after sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) of ZIKV cell extracts. After transfer, the nitrocellulose strips were saturated in PBS (pH 
7.2) containing 5% dried milk (PBSM) for 1 h at room temperature (RT). The GBS patient’s sera were 
diluted 1:1000 in PBSM containing Tween 20 (0·1%). Pan-flavivirus monoclonal antibody 4G2 was 
used as control and was diluted 1:1000. They were incubated with the strips for 1 hr at RT. After 
washings, peroxidase-conjugated goat anti-human IgM and IgG (Cappel) (diluted 1:3000) or anti-
mouse antibody IgG(H+L) (BioRad) were added and incubated for 1 h. After 3 washes in PBS, strips 
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were incubated with peroxidase chemiluminescent substrate (Immobilon®, Sigma) using standard 
conditions and detected according to the manufacturer’s recommendations. 
 
Immunosuppression test for exploration of molecular mimicry mechanisms 
Molecular mimicry was evaluated using a previously published method5. The serum from the patient 
showing highest reactivity towards GA1 without showing reactivity towards any other glycolipid 
(n°20 on Suppl. Table 2) was first diluted at 1:2000 with normal saline; then 5 ml aliquots were 
incubated overnight with 100 µg, 300 µg, and 600 µg of purified GA1 before repeating the Western 
blot analysis, using an aliquot at the initial dilution as control. Immunosuppression was also tested 
with sera n°6 after incubation with 300 µg of GA1. 
 
Combinatorial microarray 
A combinatorial microarray screening method that is based on a refinement and miniaturisation of 
our previous published combinatorial glycoarray assay6 was used to assess ZIKV GBS sera for anti-
complex antibodies. Lipid microarrays were fabricated in-house using a non-contact, piezoelectric 
dispensing system (S3 flexarrayer, Scienion, Germany).  All lipids (GM1, GM2, GA1, GD1a, GD1b, 
Phospatidylserine (PS), Cholesterol (Chol), Sulphatide (Sulph) and Galactocerebroside (GalC)) were 
obtained from Sigma (Poole, UK), with the exception of GQ1b and CTH (Matreya, Pleasant Gap, USA), 
and SGPG and LM1, which were kindly gifted by Prof. R. Yu (Georgia Regents University, Augusta, 
USA). Working solutions of each lipid was prepared at a concentration of 200µg/ml in methanol and 
heteromeric lipids were prepared by mixing equal volumes of working solution, with a total 
concentration of 200µg/ml. Microarray platforms were made by adhesion of low fluorescence PVDF 
membrane (Millipore, Nottingham, UK) on to glass microscope slides. Each slide was printed with 16 
individual arrays. For each array, approximately 500pl (100pg/spot) of lipid solution was applied at 
predetermined locations, in a grid-like pattern. As all lipids were printed in duplicate, arrays were 
designed with a line of symmetry, diagonally from top left to bottom right, with all single lipids 
printed in the first row and column. The location of all heteromeric complexes are identified in the 
array grid, as a 1:1 ratio of the two different single lipids printed in the first position of each row and 
column. Each array contained 91 different lipid targets (13 single lipids and 78 heteromeric 
complexes) in duplicate.  
Sera Testing 
Due to the limited availability of patient samples, only 41 sera at the initial time point and 27 of the 
42 patients sera at 3 months were screened by combinatorial array. Microarray slides were blocked 
in 2% Bovine Serum Albumin (BSA, Europa Bioproducts, Ely, UK) in PBS on a rocker platform, for 1 
hour at room temperature. After which, microarray slides were placed in a FAST frame device 
containing  a 16-well incubation chamber (Maine Manufacturing, Sanford,  USA),  thereby enabling 
the isolation of each of the 16 subarrays and corresponding samples, per slide.  All patient and 
control sera were diluted 1:50 in 1% BSA/PBS and 100µl was added per sub-array for 1 hour at 4˚C. 
Serum samples were aspirated from each well and washed twice with 1% BSA/PBS prior to removal 
from the FAST frame, after which microscope slides were washed twice, en masse in 1% BSA/PBS for 
15 mins, on a rocker platform. Antibody-lipid interactions were identified using Alexafluor-647 
conjugated anti- human IgG (Jackson ImmunoResearch Laboratories, West Grove USA) and 
Alexafluor-555 conjugated anti-human IgM (Life Technologies, Eugene, USA) isotype specific 
antibodies. Array slides were place in the FAST frame device once more and 100µl of secondary 
detection antibodies were applied at 4µg/ml in 1% BSA/PBS to each well, allowing identification of 
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both isotypes binding events, in each array. Slides were incubated for 1hour at 4˚C, followed by 
washing twice en masse in 1%BSA/PBS for 30mins followed by 5 mins in PBS and a further 5 mins in 
deionised water, before air drying. 
Array imaging and quantification 
Arrays were visualised with a FLAIR scanner (Sensovation, Radolfzell, Germany) and quantified using 
ProScanArray Express software (Perkin Elmer, Seer Green, UK). Median fluorescent intensity signals 
were calculated for each lipid target, with the local background signal subtracted. Mean intensity 
values were calculated for duplicate spots. Samples were tested on 3 separate occasions and the 
mean was calculated. Each of the 88 sera samples, were tested against 91 different targets, resulting 
in the measurement of 8008 individual interactions for each antibody isotype. For ease of 
comparison, data was visually displayed as heat maps (TM4-MeV MultiExperiment Viewer v4.66 
software), in which the rainbow scale was used to assign a colour to each interaction, which 
indicated the intensity of the antibody binding for that target. Hierarchical clustering was performed 
with Pearson’s correlation, to group sera with similar binding profiles. In order to establish the 
normal range of naturally occurring anti-glycolipid antibodies in this discrete population, the 95th 
percentile of the healthy controls was calculated for each target. These values were used as the 
threshold of positivity when screening the GBS cohort. As a result 5 % of all controls were identified 
as positive for each target (specificity=95%). Fisher’s exact test was used for comparison of 
proportionality. 
 
Results 
Amongst the anti-glycolipid IgG antibody repertoire, complex dependent GM2:LM1 binding was 
observed in 4 sera (3 patients and 1 control; sensitivity=7.3%, specificity= 95%), in which no binding 
was observed with the single component lipids (Suppl Figure 4). Whilst not significant, it is interesting 
to note that the one control sample had a GM2:LM1 binding intensity approximately one-third of the 
average intensity observed in the patient’s serum (1205 IU vs 3820 IU). Eight patient samples had 
strong IgG binding to GA1, as a single glycolipid (sensitivity= 19.5%, specificity 95%). Whilst not a 
significant target alone, when GA1 was in complex with sulphatide, antibody binding was enhanced, 
reaching a sensitivity of 46.3% and specificity of 95% (p=0.001), of which, 13 samples were complex 
dependent, in which antibody binding intensities were below the positivity threshold for the 
individual components (GA1 and sulphatide). In addition, a significant number of patient sera were 
positive for GA1 in complex with cholesterol and/or phosphatidylserine (48.8%), however many were 
of low binding intensity, despite being above the threshold. One patient sample had strong GM1 
single (2867IU) and complex reactivity which also reacted with GA1. One patient sample contained 
antibodies strongly reactive against single GD1a (1278 IU), but only in the 3 month sample.  This 
interaction was attenuated in complexes containing other large glycolipid molecules (namely GD1b, 
GQ1b, SGPG, LM1 and CTH). The binding profile of IgM antibodies in patient and control sera was 
very similar, in which binding to single and complexes of GA1 was frequently observed. Three of the 
41 patient samples taken at the initial time point, demonstrated IgM binding to single and complexes 
of GM1 (sensitivity=7.3%, specificity= 95%), one of which also had weak binding to GD1b. While 
heteromeric GA1:sulphatide, GA1:cholesterol and GA1:phosphatidylserine were all significant targets 
in this screen, it is interesting to note the absence of single and complex targets  (for example GM1, 
GD1a, GD1a:GD1b) frequently associated with the AMAN variant of GBS in other studies. 
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Suppl Table 1. Dengue IgG (MIA) and neutralizing (Neut.) responses by serotype.  
 
  Dengue IgG n (%) 
Dengue 
Neut.   
n (%) 
 GBS
a
 
GBS
a
 
GBS
b
 
GBS
b
 
GBS
c
 
GBS
c
 
CTR1 
CTR1 
CTR2 
CTR2 
  IgG Z
-
 IgG Z
+
  IgG Z
-
 IgG Z
+
  IgG Z
-
 IgG Z
+
  IgG Z
-
 IgG Z
+
  IgG Z
-
 IgG Z
+
  GBS
c
 
D1234 6 (33.3) 18 (75.0) 24 (57.1) 4 (28.6) 17 (60,7) 21 (50.0) 5 (38.4) 9 (31.0) 14 (33.3) 23 (31.5) 16 (64.0) 39 (39.8) 10 (15.4) 2 (40.0) 12 (17.1) 35 (85.4) 
D134 4 (22.2) 3 (12.5) 7 (16.7) 3 (21.5) 7 (25.0) 10 (23.8) 4 (30.8) 7 (24.2) 11 (26.2) 7 (9.6) 4 (16.0) 11 (11.2) 8 (12.3) 0 - 8 (11.4) 1 (2.4) 
D124 1 (5.6) 1 (4.2) 2 (4.8) - - - - 0   0 - 0 - 0 - 2 (2.7) 1 (4.0) 3 (3.1) 2 (3.1) 1 (20.0) 3 (4.3) 0 - 
D234 - - - - 0 - - - - - 0   0 - 0 - 0 - 1 (1.4) 0 - 1 (1.0) 0 - 0 - 0 - 5 (12.2) 
D14 2 (9.0) 1 (4.2) 3 (7.1) 2 (14.3) 2 (7.1) 4 (9.5) 2 (15.4) 5 (17.2) 7 (16.7) 5 (6.8) 2 (8.0) 7 (7.1) 13 (20.0) 0 - 13 (18.6) 0 - 
D13 1 (5.6) 1 (4.2) 2 (4.8) 2 (14.3) 1 (3.6) 3 (7.1) 0 - 4 (13.8) 4 (9.5) 4 (5.5) 0 - 4 (4.1) 7 (10.8) 1 (20.0) 8 (11.4) 0 - 
D12 1 (5.6) - - 1 (2.4) 1 (7.1) - - 1 (2.4) 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0  - 0 -  
D34 - - - - 0 - - - - - 0   0 - 0 - 0 - 0 - 0 - 0 - 2 (3.1) 0 - 2 (2.9) 0 - 
D1 3 (6.0) - - 3 (7.1) 1 (7.1) 1 (3.6) 2 (4.8) 0 - 4 (13.8) 4 (9.5) 15 (20.5) 2 (8.0) 17 (17.3) 8 (12.3) 1 (20.0) 9 (12.9) 0 - 
D2 - - - - 0 - - - - - 0   0 - 0 - 0 - 1 (1.4) 0 - 1 (1.0) 0 - 0 - 0 - 0 - 
D3 - - - - 0 - - - - - 0   0 - 0 - 0 - 0 - 0 - 0 - 2 (3.1) 0 - 2 (2.9) 0 - 
D4 -   -   0 - - - - - 0   0 - 0 - 0 - 4 (5.5) 0 - 4 (4.1) 1 (1.5) 0 - 1 (1.4) 0 - 
D Neg - - - - 0 - 1 (7.1) - - 1 (2.4) 2 (15.4) 0 - 2 (4.8) 11 (15.1) 0 - 11 (11.2) 12 (18.4) 0 - 12 (17.1) 0 - 
(N=) 18   24   42   14   28   42   13   29   42   73   25   98   65   5   70   41    
 
aGBS first sample; bGBS intermediate sample; cGBS last sample. 
 
Sensitivity and specificity of positivity thresholds for dengue and Zika IgG detection by MIA. These Specificity and Sensitivity values were calculated by GraphPad 
Prism 6 software based on the analysis of Receiver-Operator Characteristic (ROC) curves obtained for each antigen tested on a set of negative and positive controls.  
 
 D1 D2 D3 D4 ZIK 
Sensitivity 100% 90% 80.95% 100% 82.72% 
Specificity 100% 98.8% 100% 100% 92.11% 
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Suppl. Table 2. Zika and Dengue IgG (MIA) and neutralizing (Neut) responses. 
 
Patient 
Zika and Dengue IgG 
 
Zika and Dengue Neut
a
 
First sample   Intermediate sample   Last sample 
 
(Last sample) 
ZIKA D1 D2 D3 D4   ZIKA D1 D2 D3 D4   ZIKA D1 D2 D3 D4 
 
ZIKA D1 D2 D3 D4 
GB1 POS POS NEG POS POS   POS POS NEG POS POS   POS POS NEG POS NEG 
 
320 640 40 80 20 
GB2 NEG POS NEG POS POS   POS POS NEG POS NEG   POS POS NEG NEG NEG 
 
80 320 640 80 40 
GB3 NEG POS NEG POS POS   NEG POS NEG POS NEG   POS POS NEG POS NEG 
 
320 1280+ 1280+ 320 160 
GB4 POS POS POS POS POS   POS POS POS POS POS   POS POS NEG NEG POS 
 
320 640 320 320 80 
GB5 POS POS NEG POS NEG   POS POS POS POS POS   POS POS POS POS POS 
 
1280+ ND ND ND ND 
GB6 POS POS POS POS POS   POS POS POS POS POS   POS POS NEG NEG POS 
 
320 320 80 40 20 
GB7 POS POS POS POS POS   POS POS POS POS POS   POS POS POS POS POS 
 
80 320 160 40 0 
GB8 POS POS POS POS POS   POS POS POS POS POS   POS POS POS POS POS 
 
80 640 640 80 320 
GB9 NEG POS POS POS POS   POS POS POS POS POS   POS POS POS POS POS 
 
80 1280+ 160 160 80 
GB10 NEG POS POS POS POS   NEG POS POS POS POS   POS POS POS POS POS 
 
160 1280+ 640 160 160 
GB11 POS POS POS POS POS   POS POS POS POS POS   POS POS NEG POS POS 
 
160 1280+ 320 80 80 
GB12 POS POS POS POS POS   POS POS POS POS POS   NEG POS POS POS POS 
 
80 160 320 80 80 
GB13 POS POS POS NEG POS   POS POS NEG POS POS   NEG POS NEG POS POS 
 
160 320 640 80 80 
GB14 NEG POS POS POS POS   POS POS POS POS POS   NEG POS POS POS POS 
 
160 320 320 80 160 
GB15 POS POS NEG POS POS   NEG POS NEG POS POS   NEG POS NEG POS POS 
 
160 320 320 40 160 
GB16 NEG POS POS POS POS   NEG POS POS POS POS   NEG POS POS POS POS 
 
160 320 320 160 80 
GB17 NEG POS NEG POS POS   NEG POS NEG POS POS   NEG POS NEG POS POS 
 
320 640 640 640 320 
GB18 NEG POS POS NEG NEG   NEG POS POS NEG NEG   NEG NEG NEG NEG NEG 
 
320 160 640 80 40 
GB19 POS POS POS POS POS   POS POS NEG NEG POS   POS POS NEG NEG POS 
 
320 640 160 80 40 
GB20 NEG POS POS POS POS   POS POS NEG POS POS   POS POS NEG POS POS 
 
160 320 640 160 80 
GB21 NEG POS NEG NEG NEG   NEG NEG NEG NEG NEG   NEG NEG NEG NEG NEG 
 
160 160 320 80 80 
GB22 POS POS POS POS POS   POS POS POS POS POS   POS POS NEG NEG NEG 
 
640 320 160 160 20 
GB23 POS POS POS POS POS   POS POS POS POS POS   POS POS POS POS POS 
 
640 1280+ 320 640 40 
GB24 NEG POS NEG NEG POS   NEG POS POS POS POS   NEG POS POS POS POS 
 
640 1280+ 640 640 320 
GB25 POS POS POS POS POS   POS POS POS POS POS   POS POS NEG POS POS 
 
160 640 160 320 320 
GB26 NEG POS NEG NEG NEG   NEG POS NEG NEG NEG   POS POS NEG NEG NEG 
 
160 640 320 320 160 
GB27 POS POS POS POS POS   POS POS POS POS POS   POS POS POS POS POS 
 
1280+ 1280+ 1280+ 1280+ 640 
GB28 NEG POS POS NEG POS   NEG POS NEG NEG POS   NEG POS NEG NEG POS 
 
160 640 320 320 160 
GB29 POS POS NEG POS POS   POS POS NEG POS POS   POS POS NEG POS NEG 
 
640 1280+ 640 1280+ 20 
GB30 NEG POS NEG POS NEG   NEG POS NEG POS NEG   POS POS NEG POS NEG 
 
320 1280+ 160 1280+ 320 
GB31 POS POS POS POS POS   POS POS POS POS POS   POS POS NEG POS POS 
 
160 640 640 640 80 
GB32 POS POS POS POS POS   NEG POS POS POS POS   NEG POS POS POS POS 
 
160 160 320 160 80 
GB33 POS POS NEG NEG POS   POS POS NEG NEG POS   POS POS NEG NEG POS 
 
640 160 80 160 80 
GB34 POS POS POS POS POS   POS POS POS POS POS   POS POS NEG NEG POS 
 
320 160 10 80 160 
GB35 POS POS POS POS POS   POS POS NEG POS POS   POS POS POS POS POS 
 
640 320 40 160 40 
GB36 POS POS POS POS POS   POS POS NEG POS POS   POS POS NEG POS POS 
 
640 1280+ 320 1280+ 160 
GB37 NEG POS NEG NEG NEG   POS POS NEG NEG NEG   POS POS NEG NEG NEG 
 
1280+ 1280+ 1280+ 1280+ 80 
GB38 NEG POS POS POS POS   POS POS POS POS POS   POS POS NEG POS POS 
 
320 160 160 160 320 
GB39 NEG POS NEG POS POS   NEG POS NEG POS POS   NEG POS NEG POS POS 
 
640 1280+ 1280+ 1280+ 1280+ 
GB40 POS POS POS POS POS   POS POS POS POS POS   POS POS POS POS POS 
 
1280+ 1280+ 80 320 160 
GB41 POS POS POS POS POS   POS POS NEG POS POS   POS POS NEG POS POS 
 
640 1280+ 640 640 160 
GB42 NEG POS NEG NEG POS   NEG POS NEG NEG POS   NEG POS NEG NEG POS 
 
640 1280+ 1280+ 1280+ 1280+ 
POS 24 42 27 33 36   28 41 22 34 35   29 40 14 29 32 
 
42 41 40 41 36 
NEG 18 0 15 9 6   14 0 0 0 0   13 0 0 0 0 
 
0 0 1 0 5 
a
Neutralization titres were considered as positive if ≥ 40  
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Suppl. Table 3. Percentage of binding against glycolipids in serum of patients at admission (n=42) and 
at 3 months (n31). 
 
Patient                   At admission                       At 3 months 
 GM1 GA1 GM2 GD1a GD1b GQ1b GM1 GA1 GM2 GD1a GD1b GQ1b 
1 NEG 72% 38% NEG NEG NEG       
2 NEG 35% NEG NEG NEG NEG NEG 54% NEG NEG NEG NEG 
3 NEG 48% NEG NEG NEG NEG 51% 56% NEG 82% 53% NEG 
4 NEG 71% 59% 119% 107% NEG 141% 46% 54% 136% 162% NEG 
5 NEG NEG NEG NEG NEG NEG       
6 NEG 79% NEG NEG NEG NEG       
7 NEG 72% 44% NEG NEG NEG 78% 55% NEG 83% 90% NEG 
8 NEG NEG NEG NEG NEG NEG       
9 NEG NEG NEG 44% NEG NEG 46% NEG NEG 58% 60% NEG 
10 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
11 NEG 45% NEG NEG NEG NEG NEG 70% NEG NEG NEG NEG 
12 NEG NEG NEG NEG NEG NEG 57% 41% 42% 67% 77% NEG 
13 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
14 NEG NEG 48% NEG 57% NEG NEG NEG NEG NEG NEG NEG 
15 NEG 45% 58% 83% 51% NEG 52% 60% NEG 66% 60% NEG 
16 NEG NEG NEG 49% NEG NEG NEG NEG NEG NEG NEG NEG 
17 NEG NEG NEG 55% NEG NEG NEG NEG NEG NEG NEG NEG 
18 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
19 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
20 NEG 232% NEG NEG NEG NEG NEG 321% NEG NEG NEG NEG 
21 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
22 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
23 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
24 NEG NEG NEG NEG NEG NEG       
25 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
26 NEG 35% NEG NEG NEG NEG       
27 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
28 NEG NEG NEG 163% NEG NEG NEG NEG NEG 133% NEG NEG 
29 NEG 78% NEG NEG 37% 44% NEG 81% NEG NEG NEG NEG 
30 38% 91% NEG NEG NEG NEG 51% 77% NEG NEG NEG NEG 
31 37% 34% NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
32 NEG NEG NEG NEG NEG NEG       
33 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
34 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
35 NEG NEG NEG NEG NEG NEG       
36 NEG 56% NEG 132% 39% NEG 93% 92% NEG 138% 98% NEG 
37 48% 47% 36% NEG NEG NEG       
38 EC EC EC EC EC EC       
39 NEG NEG NEG NEG 63% 41% NEG NEG NEG NEG 73% NEG 
40 NEG NEG NEG NEG NEG NEG       
41 NEG 41% NEG NEG NEG NEG 60% 60% NEG 63% 68% NEG 
42 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
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Suppl. Figure 1 
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Suppl. Figure 2 
 
 
 
Suppl Figure 3 
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Suppl Figure 4 
